R S Doody

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi request reprint Therapeutic standards in Alzheimer disease
    R S Doody
    Baylor College of Medicine, Department of Neurology, Houston, Texas 77030, USA
    Alzheimer Dis Assoc Disord 13:S20-6. 1999
  2. doi request reprint We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development
    Rachelle S Doody
    Baylor College of Medicine, Houston, TX, USA
    Alzheimers Dement 4:S21-5. 2008
  3. pmc The Dementia and Disability Project in Thai Elderly: rational, design, methodology and early results
    Vorapun Senanarong
    Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Prannok Rd, Bangkok, Thailand
    BMC Neurol 13:3. 2013
  4. pmc Predicting progression of Alzheimer's disease
    Rachelle S Doody
    Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, 6501 Fannin Street, NB302, Houston, TX 77030, USA
    Alzheimers Res Ther 2:2. 2010
  5. doi request reprint Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study
    Rachelle S Doody
    Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, 6550 Fannin, Houston, TX 77030, USA
    Am J Alzheimers Dis Other Demen 25:155-9. 2010
  6. ncbi request reprint Meta-analysis of six-month memantine trials in Alzheimer's disease
    Rachelle Smith Doody
    Baylor College of Medicine, Houston, TX, USA
    Alzheimers Dement 3:7-17. 2007
  7. ncbi request reprint Changing patient characteristics and survival experience in an Alzheimer's center patient cohort
    R Doody
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Dement Geriatr Cogn Disord 20:198-208. 2005
  8. ncbi request reprint Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease
    R Doody
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Dement Geriatr Cogn Disord 18:227-32. 2004
  9. pmc Does APO epsilon4 correlate with MRI changes in Alzheimer's disease?
    R S Doody
    Department of Neurology and Alzheimer s Disease Research Center, Baylor College of Medicine, 6550 Fannin Suite, 1801 Houston, TX 77030, USA
    J Neurol Neurosurg Psychiatry 69:668-71. 2000
  10. ncbi request reprint A method for estimating duration of illness in Alzheimer's disease
    Rachelle Smith Doody
    Department of Neurology and Alzheimer s Disease Center, Baylor College of Medicine, Houston, TX 77030, USA
    Dement Geriatr Cogn Disord 17:1-4. 2004

Detail Information

Publications37

  1. ncbi request reprint Therapeutic standards in Alzheimer disease
    R S Doody
    Baylor College of Medicine, Department of Neurology, Houston, Texas 77030, USA
    Alzheimer Dis Assoc Disord 13:S20-6. 1999
    ..One large-scale clinical trial suggests that it has sufficient benefit and safety to join donepezil as a current standard of AD therapy...
  2. doi request reprint We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development
    Rachelle S Doody
    Baylor College of Medicine, Houston, TX, USA
    Alzheimers Dement 4:S21-5. 2008
    ..Further refinements would come by demonstration of how substantial and how enduring the antidementia benefits are...
  3. pmc The Dementia and Disability Project in Thai Elderly: rational, design, methodology and early results
    Vorapun Senanarong
    Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Prannok Rd, Bangkok, Thailand
    BMC Neurol 13:3. 2013
    ..Neuropsychiatric problems, cognitive decline, dementia, and cultural issues in elderly people also can alter the quality of life of the elderly...
  4. pmc Predicting progression of Alzheimer's disease
    Rachelle S Doody
    Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, 6501 Fannin Street, NB302, Houston, TX 77030, USA
    Alzheimers Res Ther 2:2. 2010
    ..The slowest progression group also survives longer. This baseline measure should be considered in the design of long duration Alzheimer's disease clinical trials...
  5. doi request reprint Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study
    Rachelle S Doody
    Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, 6550 Fannin, Houston, TX 77030, USA
    Am J Alzheimers Dis Other Demen 25:155-9. 2010
    ..3%). These findings support the safety of donepezil in patients with aMCI. When compared with other studies, however, the data suggest that patients with Alzheimer's tolerate donepezil better than patients with MCI...
  6. ncbi request reprint Meta-analysis of six-month memantine trials in Alzheimer's disease
    Rachelle Smith Doody
    Baylor College of Medicine, Houston, TX, USA
    Alzheimers Dement 3:7-17. 2007
    ..Safety profiles suggested excellent safety and tolerability, with no differences between the severity groups. CONCLUSIONS: Memantine consistently benefited patients in all stages of AD and was well-tolerated...
  7. ncbi request reprint Changing patient characteristics and survival experience in an Alzheimer's center patient cohort
    R Doody
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Dement Geriatr Cogn Disord 20:198-208. 2005
    ..Large and diverse dementia patient cohorts can further a variety of research programs aimed at improving diagnosis, treatment, and meaningful survival in AD...
  8. ncbi request reprint Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease
    R Doody
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Dement Geriatr Cogn Disord 18:227-32. 2004
    ....
  9. pmc Does APO epsilon4 correlate with MRI changes in Alzheimer's disease?
    R S Doody
    Department of Neurology and Alzheimer s Disease Research Center, Baylor College of Medicine, 6550 Fannin Suite, 1801 Houston, TX 77030, USA
    J Neurol Neurosurg Psychiatry 69:668-71. 2000
    ..The APO epsilon4 allele is correlated with amyloid angiopathy and other neuropathologies in Alzheimer's disease and could be associated with white matter changes. If so, there should be a dose effect...
  10. ncbi request reprint A method for estimating duration of illness in Alzheimer's disease
    Rachelle Smith Doody
    Department of Neurology and Alzheimer s Disease Center, Baylor College of Medicine, Houston, TX 77030, USA
    Dement Geriatr Cogn Disord 17:1-4. 2004
    ..There was excellent agreement between independent physician raters (rho = 0.95, p < 0.001). Caregiver estimates of duration were usually shorter because of failure to relate the first symptoms to the onset of disease...
  11. ncbi request reprint Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease
    R S Doody
    Baylor College of Medicine Alzheimer s Disease Research Center AGO 8664, Houston, Tex 77030 3498, USA
    Dement Geriatr Cogn Disord 12:295-300. 2001
    ..To compare rates of cognitive decline between probable Alzheimer's disease (AD) patients treated with long-duration cholinesterase inhibitors (ChE-Is) and those who remained untreated...
  12. ncbi request reprint Current treatments for Alzheimer's disease: cholinesterase inhibitors
    Rachelle S Doody
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    J Clin Psychiatry 64:11-7. 2003
    ..Therefore, additional therapies for Alzheimer's disease still need to be developed that include more tolerable agents with alternative mechanisms of action and broader efficacy...
  13. doi request reprint Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial
    R S Doody
    Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    Neurology 72:1555-61. 2009
    ..Treatment of mild cognitive impairment (MCI) with cholinesterase inhibitors may improve symptoms...
  14. ncbi request reprint Realistic expectations for treatment success in Alzheimer's disease
    D S Geldmacher
    Memory Disorders Program, Department of Neurology, University of Virginia, Box 800394, Charlottesville, Virginia 22908, USA
    J Nutr Health Aging 10:417-29. 2006
    ..In this article we review the natural history of AD and evidence for the effectiveness of the treatments indicated for AD: donepezil, galantamine, rivastigmine, and memantine...
  15. ncbi request reprint Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease
    R S Doody
    Department of Neurology, Baylor College of Medicine, 6550 Fannin Street, Suite 1801, Houston, TX 77030-3498, USA
    Arch Neurol 58:427-33. 2001
    ..CONCLUSIONS: Donepezil is an effective and safe drug for the long-term symptomatic treatment of mild to moderately severe AD for up to 144 weeks (2.8 years), and sustained treatment may confer some advantages...
  16. ncbi request reprint Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease
    Rachelle S Doody
    Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Drugs Aging 25:163-74. 2008
    ..Higher doses of donepezil, if safe and well tolerated, might provide further benefits for patients with AD...
  17. ncbi request reprint Influence of premorbid IQ and education on progression of Alzheimer's disease
    V N Pavlik
    Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX 77098 3926, USA
    Dement Geriatr Cogn Disord 22:367-77. 2006
    ..Years of education and measures of general intellectual function (IQ) are highly correlated. It is important to determine whether there is a relationship between education and AD outcomes that is independent of IQ...
  18. ncbi request reprint Importance of subtle amnestic and nonamnestic deficits in mild cognitive impairment: prognosis and conversion to dementia
    S D Rountree
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Dement Geriatr Cogn Disord 24:476-82. 2007
    ..To evaluate baseline characteristics and conversion to dementia in mild cognitive impairment (MCI) subtypes...
  19. ncbi request reprint A method for estimating progression rates in Alzheimer disease
    R S Doody
    Baylor College of Medicine, Department of Neurology, 6550 Fannin St, Suite 1801, Houston, TX 77030, USA
    Arch Neurol 58:449-54. 2001
    ..81, P =.002). CONCLUSION: An easily calculable rate of early disease progression can classify patients as rapid, intermediate, or slow progressors with good predictive value, even at initial presentation...
  20. ncbi request reprint Refining treatment guidelines in Alzheimer's disease
    Rachelle S Doody
    Baylor College of Medicine, Houston, Texas, USA
    Geriatrics . 2005
    ..This review will conclude with a discussion of how new data on AD treatments will potentially change current treatment parameters...
  21. doi request reprint How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease?
    Jared F Benge
    Mental Health Care Line, Michael E DeBakey Veteran s Affairs Medical Center, Houston, Tex 77030, USA
    Dement Geriatr Cogn Disord 28:63-9. 2009
    ..The current investigation used item response theory (IRT) analyses to assess the measurement properties of the ADAS-cog across the range of cognitive dysfunction in AD...
  22. ncbi request reprint The making of a self-neglect severity scale
    Carmel Bitondo Dyer
    Department of Internal Medicine, University of Texas Medical School Houston, Harris County Hospital District, USA
    J Elder Abuse Negl 18:13-23. 2006
    ..The lack of a gold standard to measure self-neglect has hampered efforts to study this phenomenon...
  23. doi request reprint Causes of aggressive behavior in patients with dementia
    Mark E Kunik
    Houston Center for Quality of Care and Utilization Studies, Health Services Research and Development Services, Houston, TX 77030, USA
    J Clin Psychiatry 71:1145-52. 2010
    ..To examine factors predicting development of aggression...
  24. ncbi request reprint Factors affecting deficit awareness in persons with dementia
    A Lynn Snow
    Mental Health Services Research and Development, Michael E DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA
    Dement Geriatr Cogn Disord 20:133-9. 2005
    ..This study examined factors affecting deficit awareness (DA) and the effects of diagnostic status (dementia and depression), measurement method and DA dimension on these relationships...
  25. ncbi request reprint Evolving early (pre-dementia) Alzheimer's disease trials: suit the outcomes to the population and study design
    R S Doody
    Effie Marie Cain Chair in Alzheimer s Disease Research, Baylor College of Medicine, Alzheimer s Disease and Memory Disorders Center, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    J Nutr Health Aging 14:299-302. 2010
    ..Outcome measures for each study design will depend upon the characteristics of the study...
  26. pmc Olfactory copy number association with age at onset of Alzheimer disease
    C A Shaw
    Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
    Neurology 76:1302-9. 2011
    ..Alzheimer disease (AD) has high heritability for occurrence and age at onset (AAO). We performed a cases-only genome-wide CNV association study for age at onset of AD...
  27. doi request reprint Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study
    Rachelle S Doody
    Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX, USA
    Lancet 372:207-15. 2008
    ..More effective treatments are needed. We assessed the safety, tolerability, and efficacy of dimebon in the treatment of patients with mild-to-moderate Alzheimer's disease...
  28. ncbi request reprint Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease
    Brian D Hoyt
    Department of Psychology, University of Houston, Houston, Tex, USA
    Arch Neurol 62:454-9. 2005
    ..However, findings regarding an association between the APOE epsilon4 allele and the rate of decline in AD have been mixed...
  29. pmc Vitamin E use is associated with improved survival in an Alzheimer's disease cohort
    Valory N Pavlik
    Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX 77098, USA
    Dement Geriatr Cogn Disord 28:536-40. 2009
    ..Vitamin E at a dose of 2,000 IU per day has been shown to delay Alzheimer's disease (AD) progression, but recent studies have questioned the safety of this dose level and the overall efficacy of vitamin E in AD treatment...
  30. ncbi request reprint Is functional decline necessary for a diagnosis of Alzheimer's disease?
    Kyung Won Park
    Department of Neurology, Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX 77030, USA
    Dement Geriatr Cogn Disord 24:375-9. 2007
    ..The purpose of this study is to examine baseline differences and annualized cognitive and functional change scores in mild Alzheimer's disease (AD) patients with and without impaired activities of daily living (ADL)...
  31. ncbi request reprint Effects of blood pressure on neuropsychological functioning in Alzheimer's disease
    Robert N Davis
    Department of Psychology, University of Houston, Houston, TX 77204 5022, USA
    Arch Clin Neuropsychol 18:19-32. 2003
    ..These findings may reflect a tendency for less severely demented patients to exhibit normal age-related changes in blood pressure, whereas abnormal patterns may develop with increased dementia severity...
  32. ncbi request reprint Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology
    R S Doody
    Department of Neurology, Baylor College of Medicine, Houston, TX, USA
    Neurology 56:1154-66. 2001
    ..To define and investigate key issues in the management of dementia and to make literature-based treatment recommendations...
  33. ncbi request reprint Survival among patients with dementia from a large multi-ethnic population
    Stephen C Waring
    Division of Epidemiology, University of Texas School of Public Health, Houston, TX 77030, USA
    Alzheimer Dis Assoc Disord 19:178-83. 2005
    ..Our findings are consistent with previous studies and provide compelling evidence that survival from onset or diagnosis of dementia depends more on age than any other factor...
  34. ncbi request reprint Dimebon as a potential therapy for Alzheimer's disease
    Rachelle S Doody
    Alzheimer s Disease Research, Baylor College of Medicine, Houston, Texas, USA
    CNS Spectr 14:14-6; discussion 16-8. 2009
    ....
  35. doi request reprint Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Centers of excellence in Alzheimer's disease: it is time to better integrate patient care and clinical research to improve the prevention and treatment of Alz
    Rachelle S Doody
    Effie Marie Cain Chair in Alzheimer s Disease Research, Baylor College of Medicine, Houston, TX, USA
    Alzheimers Dement 5:133-6. 2009
    ....
  36. pmc Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease
    David A Wolk
    Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 107:10256-61. 2010
    ....
  37. ncbi request reprint Recommendations for best practices in the treatment of Alzheimer's disease in managed care
    Howard M Fillit
    Alzheimer s Drug Discovery Foundation and Institute for the Study of Aging New York, New York 10019, USA
    Am J Geriatr Pharmacother 4:S9-S24; quiz S25-S28. 2006
    ..However, these clinical guidelines have not been updated in the past few years...